Wright collaborates with Tissue Engineering:
This article was originally published in Clinica
Executive Summary
US orthopaedics company Wright Medical Technology will set up a joint venture with Tissue Engineering to develop and distribute products for musculoskeletal applications. Tissue Engineering, based in Boston, is developing collagen-based scaffolds for ligament and tendon reconstruction, for cartilage regeneration and for use as a bone graft substitute. "These collagen scaffolds have the potential not only to repair bone and cartilage but also to re-grow ligaments and tendons," says Jack Parr, Wright's executive vice-president of R&D.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.